Janus kinase (JAK) inhibitors are a promising and new method of treating alopecia areata, giving doctors new options for ...

Patients with alopecia areata who did not respond to initial treatment with a JAKi or who did not maintain response may ...

Researchers have found in a multicentre real-world study that ritlecitinib 50 mg/day was found to be an effective and ...

Maria Hordinsky, MD, discusses exciting results in alopecia areata, including some discussed at the Winter Clinical ...

Please provide your email address to receive an email when new articles are posted on . Rezpegaldesleukin is an interleukin-2 receptor pathway agonist that may stimulate regulatory T-cell expansion ...

ARQ-255 is a topical janus kinase (JAK) inhibitor therapy specifically designed as a potential treatment for alopecia areata Proprietary Deep Dermal Drug Delivery (4D) formulation designed to deliver ...

ARQ-255 is a topical Janus kinase 1 (JAK1) inhibitor suspension formulated as a potential topical treatment for alopecia areata Proprietary Deep Dermal Drug Delivery (4D) technology formulated to ...

Achieved target product profile on the primary endpoint, with a mean percent reduction in SALT score at 36 weeks of 28.2% in the 24 µg/kg arm versus 11.2% in placebo Mean percent reduction in SALT ...

Patients with alopecia areata (AA) who do not respond to treatment with one of the three approved JAK inhibitors may get a response by switching to one of the other JAK inhibitors, a small study has ...

Neoadjuvant Osimertinib for the Treatment of Stage I-IIIA Epidermal Growth Factor Receptor–Mutated Non–Small Cell Lung Cancer: A Phase II Multicenter Study We conducted an open-label randomized ...

If you’re reading this because you’re losing your hair, you’re not alone — hair loss is a common issue affecting more than half of men by the time they’re in their forties. The most common type of ...